Gene expression : Influences over 4,000 genes, upregulates healing genes, downregulates inflammatory genes
/assets/images/provider/photos/2840805.png)
Common GI side effects (affecting more than 1 in 10 people) according to the SmPC: Nausea : The most frequent side effect, reported in approximately 44% of patients in clinical trials, usually most pronounced during the first few weeks and with dose increases Diarrhoea : Affects roughly 30% of users, typically mild to moderate and transient Vomiting : Occurs in about 24% of patients, often associated with eating too quickly or consuming large portions Constipation : Reported in approximately 24% of users, which may require dietary modification or occasional laxative use Abdominal pain or discomfort : Affects around 20% of patients, usually described as cramping or bloating Dyspepsia and reflux : Indigestion and heartburn occur in approximately 9% of users Less common but significant GI effects : Delayed gastric emptying : Whilst this is the intended pharmacological effect, in some cases it can cause persistent nausea, vomiting, and inability to tolerate food Pancreatitis : Has been reported in clinical trials and post-marketing

Cerebrolysin: Extensive clinical use provides substantial safety data
The TRIUMPH-1 phase 3 trial results are a major milestone, says Dr